@ARTICLE{
author={Stemmer Salomon M|,Manojlovic Nebojsa S|0000-0002-3639-1328,...|,Natosevic Sladjana|,...|,(broj koautora 21)|},
year={2021},
title={Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial},
journal={CANCERS},
volume={13},
number={2},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Stemmer Salomon M|,Manojlovic Nebojsa S|0000-0002-3639-1328,...|,Natosevic Sladjana|,...|,(broj koautora 20)|},
year={2019},
title={A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A(3) adenosine receptor agonist (A(3)AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
}